申请人:Hoffmann-La Roche Inc.
公开号:US04959361A1
公开(公告)日:1990-09-25
The invention relates to compounds of the formula ##STR1## wherein X is --CH.dbd.CH-- or S; R.sub.1 is lower alkyl, lower alkoxy or trifluoromethyl; R.sub.2 is hydrogen, lower alkyl, lower alkoxy, hydroxy or alkanoyloxy; R.sub.3 and R.sub.4, independently, are hydrogen, chlorine, fluorine, lower alkyl or lower alkoxy; s is an integer from 0 to 1, provided that when s is 1, R.sub.2 cannot be hydroxy, lower alkoxy or alkanoyloxy; R.sub.5 is a radical of the formula R.sub.6 --(CH.sub.2).sub.n -- or R.sub.7 --O--(CH.sub.2).sub.m -- wherein R.sub.6 and R.sub.7 are aryl or a heterocyclic radical, n is an integer of from 0 to 2 and m is an integer of from 1 to 2, provided that, when n is 0, R.sub.6 must be attached through a carbon to carbon bond, and provided that R.sub.7 is always attached through a carbon to oxygen bond, and, when at least one asymmetric carbon is present, its enantiomers and racemates, and pharmaceutically acceptable acid addition salts thereof. The compounds of formula I exhibit activity as platelet activating factor (PAF) antagonists and are, therefore, useful in disease states characterized by excess platelet activating factor or for the prevention and treatment of cardiovascular diseases, pulmonary diseases, immunological disorders, inflammatory diseases, dermatological disorders, shock or transplant rejection.
本发明涉及通式##STR1##的化合物,其中X为--CH=CH--或S;R1为低级烷基、低级烷氧基或三氟甲基;R2为氢、低级烷基、低级烷氧基、羟基或烷酰氧基;R3和R4各自独立地为氢、氯、氟、低级烷基或低级烷氧基;s为0至1的整数,但当s为1时,R2不能为羟基、低级烷氧基或烷酰氧基;R5为通式R6--(CH2)n--或R7--O--(CH2)m--的基团,其中R6和R7为芳基或杂环基团,n为0至2的整数,m为1至2的整数,但当n为0时,R6必须通过碳-碳键连接,且R7始终通过碳-氧键连接,当存在至少一个不对称碳时,包括其对映体和外消旋体,以及药学上可接受的酸加成盐。通式I的化合物表现出作为血小板活化因子(PAF)拮抗剂的活性,因此可用于治疗以过量血小板活化因子为特征的疾病状态,或用于预防和治疗心血管疾病、肺部疾病、免疫紊乱、炎症性疾病、皮肤病、休克或移植排斥反应。